Skip to main content
SpringerLink
Log in

Optimal Dosage of ACE Inhibitors in Older Patients

  • Clinical Pharmacology
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

Despite having lower levels of plasma renin activity than younger individuals, elderly patients with hypertension respond well to ACE inhibitors and the drugs have few adverse effects. Plasma concentrations of the active ACE inhibitor are generally higher in the elderly because of decreased renal clearance. These altered pharmacokinetics, combined with impairment of cardiovascular reflexes and the increasing prevalence of heart failure and renal impairment with age, render elderly patients more susceptible to first-dose hypotension. Although many studies have shown that standard dosages are well tolerated, it is safer to use lower initial dosages of ACE inhibitors in elderly hypertensive patients because hypotensive reactions are not always predictable. The maintenance dosage may be determined more by the presence of renal disease or heart failure than by age per se. In elderly patients with heart failure, ACE inhibitors should be introduced even more cautiously, using low dosages and preferably under supervision. It may also be necessary to interrupt diuretic treatment for a few days to prevent severe hypotension. The ACE inhibitor dosage should then be titrated up to the maximum that is well tolerated, as this appears to offer the greatest benefit.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Case DB, Wallace JM, Keim HJ, et al. Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme. N Engl J Med 1977; 296: 641–6

    PubMed  CAS  Google Scholar 

  2. Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients. J Cardiovasc Pharmacol 1985; 7 Suppl. 1: 52S–5S

    Google Scholar 

  3. Materson BJ, Reda DJ, Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Single-drug therapy for hypertension in men: a comparison of six antihypertensive agents with placebo. N Engl J Med 1993; 328: 914–21

    PubMed  CAS  Google Scholar 

  4. Tuck ML, Williams GH, Cain JP, et al. Relation of age, diastolic pressure and known duration of hypertension to presence of low renin essential hypertension. Am J Cardiol 1973; 32: 637–42

    PubMed  CAS  Google Scholar 

  5. Meade TW, Imeson JD, Gordon D, et al. The epidemiology of plasma renin. Clin Sci 1983; 64: 273–80

    PubMed  CAS  Google Scholar 

  6. Belmin J, Lévy BI, Michel J-B. Changes in the renin-angiotensin-aldosterone axis in later life. Drugs Aging 1994; 5: 391–400

    PubMed  CAS  Google Scholar 

  7. Tsunoda K, Abe K, Goto T, et al. Effect of age on the renin-angiotensin-aldosterone system in normal subjects: simultaneous measurement of active and inactive renin, renin substrate, and aldosterone in plasma. J Clin Endocrinol Metab 1986; 62: 384–9

    PubMed  CAS  Google Scholar 

  8. Weidmann P, de Myttenaere-Bursztein S, Maxwell MH, et al. Effect of aging on plasma renin and aldosterone in normal man. Kidney Int 1975; 8: 325–33

    PubMed  CAS  Google Scholar 

  9. Crane MG, Harris JJ. Effect of aging on renin activity and aldosterone excretion. J Lab Clin Med 1976; 87: 947–59

    PubMed  CAS  Google Scholar 

  10. Nakamaru M, Ogihara T, Higaki J, et al. Effect of age on active and inactive plasma renin in normal subjects and in patients with essential hypertension. J Am Geriatr Soc 1981; 29: 379–82

    PubMed  CAS  Google Scholar 

  11. Takeda R, Morimoto S, Ushida K, et al. Effect of age on plasma aldosterone response to exogenous angiotensin II in normotensive subjects. Acta Endocrinol 1980; 94: 552–8

    PubMed  CAS  Google Scholar 

  12. Lijnen P, Fagard R, Groeseneken D, et al. The hypotensive effect of captopril in hypertensive patients is age-related. Methods Find Exp Clin Pharmacol 1983; 5: 655–60

    PubMed  CAS  Google Scholar 

  13. Corea L, Bentivoglio M, Verdecchia P, et al. Converting-enzyme inhibition vs diuretic therapy as first therapeutic approach to the elderly hypertensive patient. Curr Ther Res 1984; 36: 347–52

    Google Scholar 

  14. Lees KR, Reid JL. Age and the pharmacokinetics and pharmacodynamics of chronic enalapril treatment. Clin Pharmacol Ther 1987; 41: 597–602

    PubMed  CAS  Google Scholar 

  15. Lees KR, Green ST, Reid JL. Influence of age on the pharmacokinetics and pharmacodynamics of perindopril. Clin Pharmacol Ther 1988; 44: 418–25

    PubMed  CAS  Google Scholar 

  16. De Bock V, Mets T, Romagnoli M, et al. Captopril treatment of chronic heart failure in the very old. J Gerontol 1994; 49: M148–52

    PubMed  Google Scholar 

  17. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med 1986; 314: 1657–64

    PubMed  CAS  Google Scholar 

  18. Man In’t Veld AJ, Schicht IM, Derkx FH, et al. Effects of an angiotensin-converting enzyme inhibitor (captopril) on blood pressure in anephric subjects. BMJ 1980; 280: 288–90

    Google Scholar 

  19. Dzau VJ. Vascular renin-angiotensin system in hypertension: new insights into the mechanism of action of angiotensin converting enzyme inhibitors. Am J Med 1988; 84: 4–8

    PubMed  CAS  Google Scholar 

  20. Opie LH. Angiotensin converting enzyme inhibitors: scientific basis for clinical use. 2nd ed. New York: Wiley-Liss, 1994

    Google Scholar 

  21. Leonetti G, Cuspidi C. Choosing the right ACE inhibitor: a guide to selection. Drugs 1995; 49: 516–35

    PubMed  CAS  Google Scholar 

  22. Razzetti R, Acerbi D. Pharmacokinetic and pharmacologic properties of delapril, a lipophilic nonsulfhydryl angiotensinconverting enzyme inhibitor. Am J Cardiol 1995; 75: 7F–12F

    PubMed  CAS  Google Scholar 

  23. Schwartz JB, Taylor A, Abernethy D, et al. Pharmacokinetics and pharmacodynamics of enalapril in patients with congestive heart failure and patients with hypertension. J Cardiovasc Pharmacol 1985; 7: 767–76

    PubMed  CAS  Google Scholar 

  24. Ferrannini E, Seghieri G, Muscelli E. Insulin and the renin-angiotensin-aldosterone system: influence of ACE inhibition. J Cardiovasc Pharmacol 1994; 24 Suppl. 3: 61S–9S

    Google Scholar 

  25. Macdonald N-J, Sioufi A, Howie CA, et al. The effects of age on the pharmacokinetics and pharmacodynamics of single oral doses of benazepril and enalapril. Br J Clin Pharmacol 1993; 36: 205–9

    PubMed  CAS  Google Scholar 

  26. Kaiser G, Ackermann R, Dieterle W, et al. Pharmacokinetics and pharmacodynamics of the ACE inhibitor benazepril hydrochloride in the elderly. Eur J Clin Pharmacol 1990; 38: 379–85

    PubMed  CAS  Google Scholar 

  27. Macdonald N-J, Elliott HL, Hughes DM, et al. A comparison in young and elderly subjects of the pharmacokinetics and pharmacodynamics of single and multiple doses of benazepril. Br J Clin Pharmacol 1993; 36: 201–4

    PubMed  CAS  Google Scholar 

  28. Creasey WA, Funke PT, McKinstry DN, et al. Pharmacokinetics of captopril in elderly healthy male volunteers. J Clin Pharmacol 1986; 26: 264–8

    PubMed  CAS  Google Scholar 

  29. Williams PE, Brown AN, Rajaguru S, et al. A pharmacokinetic study of cilazapril in elderly and young volunteers. Br J Clin Pharmacol 1989; 27: 211S–5S

    PubMed  CAS  Google Scholar 

  30. Hockings N, Ajayi A A, Reid JL. Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. Br J Clin Pharmacol 1986; 21: 341–8

    PubMed  CAS  Google Scholar 

  31. Levinson B, Sugerman AA, Couchman T, et al. Advanced age per se has no influence on the kinetics of the active diacid of fosenopril (F) [abstract]. J Clin Pharmacol 1986; 26: 555

    Google Scholar 

  32. Cirillo VJ, Till AE, Gomez HJ, et al. Effect of age on lisinopril pharmacokinetics [abstract]. Clin Pharmacol Ther 1986; 39: 187

    Google Scholar 

  33. Gautam PC, Vargas E, Lye M. Pharmacokinetics of lisinopril (MK521) in healthy young and elderly subjects and in elderly patients with cardiac failure. J Pharm Pharmacol 1987; 39: 929–31

    PubMed  CAS  Google Scholar 

  34. Hosie J, Berghoff W, Frank GJ, et al. Pharmacokinetics of once-daily oral quinapril HC1 in young subjects and elderly patients [abstract no. F029]. International Symposium on ACE Inhibition: 1989 Feb 14–17; London. London: GCC Ltd, 1989

    Google Scholar 

  35. Posvar EL, Sedman AJ. ACE inhibitors in the elderly. Angiology 1991; 42: 387–96

    PubMed  CAS  Google Scholar 

  36. Meyer BH, Muller FO, Badian M, et al. Pharmacokinetics of ramipril in the elderly. Am J Cardiol 1987; 59: 33D–7D

    PubMed  CAS  Google Scholar 

  37. Gilchrist WJ, Beard K, Manhem P, et al. Pharmacokinetics and effects on the renin-angiotensin system of ramipril in elderly patients. Am J Cardiol 1987; 59: 28D–32D

    PubMed  CAS  Google Scholar 

  38. Grass P, Gerbeau C, Kutz K. Spirapril: pharmacokinetic properties and drug interactions. Blood Press 1994; 3 Suppl. 2: 7–13

    Google Scholar 

  39. Arner P, Wade A, Engfeldt P, et al. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2 mg to young and elderly patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1994; 23 Suppl. 4: 44S–9S

    Google Scholar 

  40. Greenblatt DJ, Sellers EM, Shader RI. Drug therapy: drug disposition in old age. N Engl J Med 1982; 306: 1081–8

    PubMed  CAS  Google Scholar 

  41. Sica DA, Cutler RE, Parmer RJ, et al. Comparison of the steadystate pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency. Clin Pharmacokinet 1991; 20: 420–7

    PubMed  CAS  Google Scholar 

  42. Ajayi AA, Hockings N, Reid JL. Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat. Br J Clin Pharmacol 1986; 21: 349–57

    PubMed  CAS  Google Scholar 

  43. Mets TE Drug-induced orthostatic hypotension in older patients. Drugs Aging 1995; 6: 219–28

    PubMed  CAS  Google Scholar 

  44. Tjoa HI, Kaplan NM. Treatment of hypertension in the elderly. JAMA 1990; 264: 1015–8

    PubMed  CAS  Google Scholar 

  45. Cleland JF, Dargie HJ, McAlpine H, et al. Severe hypotension after first dose of enalapril in heart failure. BMJ 1985; 291: 1309–12

    PubMed  CAS  Google Scholar 

  46. Hodsman GP, Isles CG, Murray GD, et al. Factors related to first dose hypotensive effect of captopril: prediction and treatment. BMJ 1983; 286: 832–4

    PubMed  CAS  Google Scholar 

  47. Packer M, Kessler PD, Gottlieb SS. Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management. Postgrad Med J 1986; 62 Suppl. 1: 179–82

    PubMed  Google Scholar 

  48. Todd PA, Heel RC. Enalapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 1986; 31: 198–248

    PubMed  CAS  Google Scholar 

  49. Webster J. Angiotensin converting enzyme inhibitors in the clinic: first-dose hypotension. J Hypertens 1987; 5 Suppl. 3: 27S–30S

    Google Scholar 

  50. Capewell S, Capewell A. ‘First dose’ hypotension and venodilatation [letter]. Br J Clin Pharmacol 1991; 31: 213–5

    PubMed  CAS  Google Scholar 

  51. Cody RJ. Optimising ACE inhibitor therapy of congestive heart failure: insights from pharmacodynamic studies. Clin Pharmacokinet 1993; 24: 59–70

    PubMed  CAS  Google Scholar 

  52. CONSENSUS (Co-Operative New Scandinavian Enalapril Survival Study) Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316: 1429–35

    Google Scholar 

  53. McLay JS, McMurray J, Bridges A, et al. Practical issues when initiating captopril therapy in chronic heart failure: what is the appropriate dose and how long should patients be observed? Eur Heart J 1992; 13: 1521–7

    PubMed  CAS  Google Scholar 

  54. Shionoiri H. Pharmacokinetic drug interactions with ACE inhibitors. Clin Pharmacokinet 1993; 25: 20–58

    PubMed  CAS  Google Scholar 

  55. Webb DJ, Cockcroft JR. Captopril in congestive cardiac failure [letter]. BMJ 1989; 299: 1283

    PubMed  CAS  Google Scholar 

  56. Capewell S, Taverner D, Hannan WJ, et al. Acute and chronic arterial and venous effects of captopril in congestive cardiac failure. BMJ 1989; 299: 942–5

    PubMed  CAS  Google Scholar 

  57. Ajayi AA, Campbell BC, Meredith PA, et al. The effect of captopril on the reflex control of heart rate: possible mechanisms. Br J Clin Pharmacol 1985; 20: 17–25

    PubMed  CAS  Google Scholar 

  58. Campbell BC, Sturani A, Reid JL. Evidence of parasympathetic activity of the angiotensin converting enzyme inhibitor, captopril, in normotensive man. Clin Sci 1985; 68: 49–56

    PubMed  CAS  Google Scholar 

  59. Packer M. Converting-enzyme inhibition for severe chronic heart failure: views from a skeptic. Int J Cardiol 1985; 7: 111–20

    PubMed  CAS  Google Scholar 

  60. Semple PF, Thoren P, Lever AF. Vasovagal reactions to cardiovascular drugs: the first dose effect. J Hypertens 1988; 6: 601–6

    PubMed  CAS  Google Scholar 

  61. Mark AL. The Bezold-Jarisch reflex revisited: clinical implications of inhibitory reflexes originating in the heart. J Am Coll Cardiol 1983; 1: 90–102

    PubMed  CAS  Google Scholar 

  62. MacFadyen RJ, Lees KR, Reid JL. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study. Br Heart J 1991; 66: 206–11

    PubMed  CAS  Google Scholar 

  63. Mets T, De Bock V, Praet JP. First-dose hypotension, ACE inhibitors, and heart failure in the elderly [letter]. Lancet 1992; 339: 1487

    PubMed  CAS  Google Scholar 

  64. MacFadyen RJ, Lees KR, Reid JL. Double blind controlled study of low dose intravenous perindoprilat or enalaprilat infusion in elderly patients with heart failure. Br Heart J 1993; 69: 293–7

    PubMed  CAS  Google Scholar 

  65. Lees KR, MacFadyen RJ, Reid JL. Tissue angiotensin converting enzyme inhibition: relevant to clinical practice? Am J Hypertens 1990; 3(11): 266S–72S

    PubMed  CAS  Google Scholar 

  66. Reid JL, MacFadyen RJ, Squire IB, et al. Blood pressure response to the first dose of angiotensin-converting enzyme inhibitors in congestive heart failure. Drugs Today 1995; 31 Suppl. A: 33–7

    Google Scholar 

  67. Beard K, Bulpitt C, Mascie-Taylor H, et al. Management of elderly patients with sustained hypertension. BMJ 1992; 304: 412–6

    PubMed  CAS  Google Scholar 

  68. Burois JF. Practical considerations in treating the elderly hypertensive patient. Am J Med 1991; 90 Suppl. 4B: 28S–31S

    Google Scholar 

  69. Jenkins AC, Knill JR, Dreslinski GR. Captopril in the treatment of the elderly hypertensive patient. Arch Intern Med 1985; 145: 2029–31

    PubMed  CAS  Google Scholar 

  70. Chalmers D, Dombey S, Lawson D. Post-marketing surveillance study of captopril (for hypertension): a preliminary report. Br J Clin Pharmacol 1987; 24: 343–50

    PubMed  CAS  Google Scholar 

  71. Postma CT, Dennesen PJ, de Boo T, et al. First dose hypotension after captopril: can it be predicted? A study of 240 patients. J Hum Hypertens 1992; 6: 205–9

    PubMed  CAS  Google Scholar 

  72. Penner SB, Mitenko PA, Aoki FY, et al. Long-term captopril in young and old patients with mild hypertension. J Clin Pharmacol 1991; 31: 65–71

    PubMed  CAS  Google Scholar 

  73. Cooper WD, Sheldon D, Brown D, et al. Post-marketing surveillance of enalapril: experience in 11 710 hypertensive patients in general practice. J R Coll Gen Pract 1987; 37: 346–9

    PubMed  CAS  Google Scholar 

  74. Mulinari R, Gavras I, Gavras H. Efficacy and tolerability of enalapril monotherapy in mild-to-moderate hypertension in older patients compared to younger patients. Clin Ther 1987; 9: 678–89

    PubMed  CAS  Google Scholar 

  75. Smith WM, Kulaga SF, Moncloa F, et al. Overall tolerance and safety of enalapril. J Hypertens 1984; 2 Suppl. 2: 113–7

    CAS  Google Scholar 

  76. Taylor SH. A comparison of the efficacy and safety of quinapril with that of enalapril in the treatment of mild to moderate essential hypertension. Angiology 1989; 40: 382–8

    PubMed  CAS  Google Scholar 

  77. Schnaper HW. Use of quinapril in the elderly patient. Am J Hypertens 1990; 3(11): 278S–82S

    PubMed  CAS  Google Scholar 

  78. Knapp LE, Frank GJ, McLain R, et al. The overall safety and tolerability of quinapril. J Cardiovasc Pharmacol 1990; 15 Suppl. 2: 553–62

    Google Scholar 

  79. Schnaper HW. Angiotensin-converting enzyme inhibitors for systemic hypertension in young and elderly patients. Am J Cardiol 1992; 69: 54C–8C

    PubMed  CAS  Google Scholar 

  80. Merrill D, Nelson E, Wilson S. A dose-response study of the antihypertensive activity of lisinopril in elderly patients [abstract]. Am J Hypertens 1991; 4: 21A

    Google Scholar 

  81. Suraniti S, Beirut G, Marre M, et al. Antihypertensive efficacy and acceptability of perindopril in elderly hypertensive patients. Am J Cardiol 1993; 71: 28E–31E

    PubMed  CAS  Google Scholar 

  82. Wilking SV, Belanger A, Kannel WB, et al. Determinants of isolated systolic hypertension. JAMA 1988; 260: 3451–5

    PubMed  CAS  Google Scholar 

  83. Kannel WB, Wolf PA, McGee DL, et al. Systolic blood pressure, arterial rigidity, and risk of stroke: the Framingham study. JAMA 1981; 245: 1225–9

    PubMed  CAS  Google Scholar 

  84. O’Malley K, McCormack P, O’Brien ET. Isolated systolic hypertension: data from the European Working Party on High Blood Pressure in the Elderly. J Hypertens 1988; 6 Suppl. 1: 105S–8S

    Google Scholar 

  85. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of SHEP. JAMA 1991; 265: 3255–64

    Google Scholar 

  86. Silagy CA, McNeil JJ, McGrath BP. Crossover comparison of atenolol, enalapril, hydrochlorothiazide and isradipine for isolated systolic systemic hypertension. Am J Cardiol 1992; 70: 1299–305

    PubMed  CAS  Google Scholar 

  87. Tomlinson B, Woo J, Critchley JA, et al. Sustained-release isradipine compared with spirapril in the treatment of elderly patients with isolated systolic hypertension. Am J Hypertens 1994; 7: 35S–9S

    PubMed  CAS  Google Scholar 

  88. Webster J, Fowler G, Jeffers TA, et al. A comparison of amlodipine with enalapril in the treatment of isolated systolic hypertension. Br J Clin Pharmacol 1993; 35: 499–505

    PubMed  CAS  Google Scholar 

  89. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302

    Google Scholar 

  90. Kostis JB, Shelton BJ, Yusuf S, et al. Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. Am Heart J 1994; 128: 358–64

    PubMed  CAS  Google Scholar 

  91. Lang RM, DiBianco R, Enalapril-Captopril Investigators. First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multi-center study. Am Heart J 1994; 128: 551–6

    PubMed  CAS  Google Scholar 

  92. Foy SG, Crozier IG, Turner JG, et al. Comparison of enalapril versus captopril on left ventricular function and survival three months after acute myocardial infarction (the ‘PRACTICAL’ study). Am J Cardiol 1994; 73: 1180–6

    PubMed  CAS  Google Scholar 

  93. Swedberg K, Held P, Kjekhus J, et al. Effects of early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327: 678–84

    PubMed  CAS  Google Scholar 

  94. Reid JL. Angiotensin-converting enzyme inhibitors in the elderly. BMJ 1987; 295: 943–4

    PubMed  CAS  Google Scholar 

  95. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: randomised study of oral captopril in over 50 000 patients with suspected acute myocardial infarction. Circulation 1993; 88 Suppl.: 1–394

    Google Scholar 

  96. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669–77

    PubMed  CAS  Google Scholar 

  97. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–10

    PubMed  CAS  Google Scholar 

  98. Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI-3). Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115–22

    Google Scholar 

  99. Acute Infarction Ramipril Efficacy Study Investigators (AIRE). Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–8

    Google Scholar 

  100. Cleland JGF, Hubbard WN, Pittard J, et al. ACE inhibitors in heart failure: what dose? Postgrad Med J 1995; 71: 65–6

    PubMed  CAS  Google Scholar 

  101. Powell JS, Clozel JP, Muller RK, et al. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science 1989; 245: 186–8

    PubMed  CAS  Google Scholar 

  102. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990; 15 Suppl. 5: S65–72

    PubMed  CAS  Google Scholar 

  103. Pacher R, Globits S, Bergler KJ, et al. Clinical and neurohumoral response of patients with severe congestive heart failure treated with two different captopril dosages. Eur Heart J 1993; 14: 273–8

    PubMed  CAS  Google Scholar 

  104. Vagelos R, Nejedly M, Willson K, et al. Comparison of low versus high dose enalapril therapy for patients with severe congestive heart failure [abstract]. J Am Coll Cardiol 1991; 17: 275A

    Google Scholar 

  105. Riegger GA. Effects of quinapril on exercise tolerance in patients with mild to moderate heart failure. Eur Heart J 1991; 12: 705–11

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology, Chinese University of Hong Kong, Shatin, Hong Kong

    Brian Tomlinson

Authors
  1. Brian Tomlinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tomlinson, B. Optimal Dosage of ACE Inhibitors in Older Patients. Drugs & Aging 9, 262–273 (1996). https://doi.org/10.2165/00002512-199609040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199609040-00004

Keywords

Search

Navigation